ivonescimab
akesobio
['sclc', 'ak112', 'nsclc']
#asco22 discussion of posters focused on overcoming immunotherapy resistance in nsclc led by dr. including #9019 on ak112 (pd-1/vegf bispecific) from dr. yuangyuan zhao. rr 40% and mpfs 6.5m in cohort 3 (post platinum chemo and io). 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him